Adriann Sax

Adriann Sax is a co-founder of Vetigenics and serves as Chief Executive Officer. Adriann is responsible for leading and implementing long and short-term initiatives and overseeing business development, fundraising planning and implementation.

As a serial entrepreneur, Adriann was also a founding member of Kadmon Inc. where she led and transformed all aspects of the commercial business. Before Kadmon, Adriann was EVP, BD and Strategy, for King Pharmaceuticals, implementing a renewed, growth strategy leading to the company’s sale to Pfizer in 2010 for $6.5B. She also served as Chief Business Officer, Head of U.S Operations for Symphogen, CEO of Orsenix and as Entrepreneur in Residence at Fortress Biotech leading many successful investments including licensing the Oncogenuity foundation technology from Columbia.

Adriann started her career at Sterling Drug progressing through a series of operating and executive roles with established companies such as Merck, Bristol Myers Squibb and Roche, and led the global launches of leading oncology and immunology drugs. Adriann holds an MBA from the Keller Graduate School and BS in Animal Science from the University of Delaware. She is an active advisor and board member for many industry associations, academic institutions, and nonpublic company boards.